Beam Therapeutics BEAM 深 沪
已收盘 04-19 16:00:00 美东时间
23.90
-0.410
-1.69%
华盛通- 最 高24.94
- 今 开24.14
- 成交量 453.70万股
- 最 低 23.64
- 昨 收 24.31
- 总市值 19.52亿
- 52周最高 49.50
- 市盈率 静 --
- 换手率 5.56%
- 52周最低 16.95
- 委 比 0.00%
- 总股本 8165.77万
- 历史最高 138.522
- 量 比 2.71
- 振 幅 5.35%
- 历史最低 13.00
- 每 手 1
- 风险率 4.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO:
04-13 01:55
Verve drops after pausing trial enrollments for lead asset
Gene editing company Verve Therapeutics (NASDAQ:VERV) lost ~31% premarket Tuesday after announcing its decision to pause patient enrollments in its Heart-1 Phase 1b clinical trial for its lead asset V...
04-02 19:34
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
In the last three months, 4 analysts have published ratings on Beam Therapeutic...
03-27 23:01
BMO Capital Maintains Outperform on Beam Therapeutics, Maintains $57 Price Target
BMO Capital analyst Kostas Biliouris maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price target.
03-27 22:12
比特币休整，meme炒作轮换至Base链
文章转载来源： 比推BitPush 作者：Mary Liu，比推 BitpushNews 今日加密市场涨跌互现，截止当天美股收盘，比特币跌破 7 万美元，以太坊...
03-27 18:54
Biotech Roundtable: Is CRISPR all it's cracked up to be?
CRISPR gene editing technology has been heralded as a revolutionary breakthrough in drug development, enabling scientists to potentially cure genetic diseases by modifying the genes that cause them. T...
03-26 23:43
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
03-26 18:20
LG ANNOUNCES PRICING AND AVAILABILITY OF AWARD-WINNING PROJECTOR - LG CINEBEAM Q
With a 360-degree Rotatable Handle and Auto Screen Adjustment Feature, the Late...
03-21 03:30
巴克莱：维持Beam Therapeutics(BEAM.US)持股观望评级，目标价由26.00美元调整至42.00美元。
巴克莱：维持Beam Therapeutics(BEAM.US)持股观望评级，目标价由26.00美元调整至42.00美元。
02-29 12:10
Recap: Beam Therapeutics Q4 Earnings
Beam Therapeutics (NASDAQ:BEAM) reported its Q4 earnings results on Tuesday, Fe...
02-27 21:25
